Literature DB >> 35172405

[Effectiveness of structural bone graft in total hip arthroplasty for Hartofilakidis type developmental dysplasia of the hip].

Xiaogang Zhang1, Li Cao1.   

Abstract

OBJECTIVE: To summarize the effectiveness of acetabulum reconstruction with autologous femoral head structural bone graft in total hip arthroplasty (THA) for Hartofilakidis type Ⅱ developmental dysplasia of the hip (DDH).
METHODS: A clinical data of 24 patients (27 hips) with Hartofilakidis type Ⅱ DDH, who underwent acetabulum reconstruction with autologous femoral head structural bone graft in primary THA between October 2012 and October 2020, was retrospectively analyzed. There were 3 males and 21 females, with an average age of 40 years (range, 20-58 years). The body mass index was 19.5-35.0 kg/m² with an average of 25.0 kg/m². There were 21 cases of unilateral hip and 3 cases of bilateral hips. The hip Harris score was 51.1±10.0. The leg length discrepancy of unilateral hip patients was (19.90±6.24) mm. The intraoperative blood loss, wound healing, and complications were recorded. The postoperative bone union, coverage rates of acetabular prosthesis and bone graft, and aseptic loosening of the prosthesis were evaluated based on X-ray films, and the improvement of hip function was observed by Harris score.
RESULTS: The intraoperative blood loss was 50-1000 mL (median, 350 mL). All incisions healed by first intention, and no fracture, hematoma, infection, or other complications occurred. Sciatic nerve injury occurred in 1 case (1 hip) and deep venous thrombosis occurred in 1 case (1 hip). All patients were followed up 15-103 months (median, 40.5 months). At last follow-up, Harris score was 92.6±4.1 and the difference was significant when compared with preoperative value ( t=-28.043, P=0.000). No hip prosthesis needed revision. X-ray films showed that the coverage rate of acetabular prosthesis was 91%-100% (mean, 97.8%), and the coverage rate of bone graft was 13%-46% (mean, 23.8%). The healing time of bone graft was 3-6 months (mean, 4.7 months). At last follow-up, all bone grafts completely healed without any signs of collapse. There was no graft resorption, ectopic ossification or osteolysis, or obvious aseptic loosening of the acetabular and femoral prostheses. The leg length discrepancy of unilateral hip patients was (2.86±2.18) mm, and the difference was significant when compared with preoperative value ( t=17.028, P=0.000).
CONCLUSION: For Hartofilakidis type Ⅱ DDH patients, if the lateral acetabular prosthesis not covered by the host bone exceeds 5 mm in primary THA, autologous femoral head can be used for structural bone grafting, and the short- and mid-term effectiveness are favorable.

Entities:  

Keywords:  Developmental dysplasia of the hip; acetabular bone defect; structural bone graft; total hip arthroplasty

Mesh:

Year:  2022        PMID: 35172405      PMCID: PMC8863526          DOI: 10.7507/1002-1892.202109098

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  21 in total

1.  Minimum 10-year radiographic follow-up of a cementless acetabular component for primary total hip arthroplasty with a bulk autograft.

Authors:  Shigehiro Inoue; Motoyuki Horii; Hiroshi Suehara; Keiichiro Ueshima; Toshiki Shiga; Mikihiro Fujioka; Kenji Takahashi; Takeshi Asano; Wook-Choel Kim; Masako Nakagawa; Toshikazu Kubo
Journal:  J Orthop Sci       Date:  2003       Impact factor: 1.601

2.  Ileal atresia after fetoscopic laser photocoagulation for twin-to-twin transfusion syndrome--a case report.

Authors:  Mamoru Morikawa; Haruhiko Sago; Takashi Yamada; Satoshi Hayashi; Takahiro Yamada; Kazutoshi Cho; Hideto Yamada; Michihiro Kitagawa; Hisanori Minakami
Journal:  Prenat Diagn       Date:  2008-11       Impact factor: 3.050

3.  Cementless acetabular component with or without upward placement in dysplasia hip: Early results from a prospective, randomised study.

Authors:  Zhiqi Zhang; Peihui Wu; Zhiyu Huang; Baoxi Yu; Hong Sun; Ming Fu; Yan Kang; Weiming Liao
Journal:  J Orthop       Date:  2017-06-27

Review 4.  Congenital hip disease in adults: terminology, classification, pre-operative planning and management.

Authors:  T Karachalios; G Hartofilakidis
Journal:  J Bone Joint Surg Br       Date:  2010-07

5.  Ectopic ossification following total hip replacement. Incidence and a method of classification.

Authors:  A F Brooker; J W Bowerman; R A Robinson; L H Riley
Journal:  J Bone Joint Surg Am       Date:  1973-12       Impact factor: 5.284

6.  Uncemented acetabular components with femoral head autograft for acetabular reconstruction in developmental dysplasia of the hip: a concise follow-up report at a mean of twenty years.

Authors:  Matthew P Abdel; Louis S Stryker; Robert T Trousdale; Daniel J Berry; Miguel E Cabanela
Journal:  J Bone Joint Surg Am       Date:  2014-11-19       Impact factor: 5.284

7.  Favorable Results of Primary Total Hip Arthroplasty With Acetabular Impaction Bone Grafting for Large Segmental Bone Defects in Dysplastic Hips.

Authors:  Toshiki Iwase; Daigo Morita; Tadashi Ito; Genta Takemoto; Kazuya Makida
Journal:  J Arthroplasty       Date:  2016-04-04       Impact factor: 4.757

8.  Medial Protrusio Technique in Cementless Total Hip Arthroplasty for Developmental Dysplasia of the Hip: A Prospective 6- to 9-Year Follow-Up of 43 Consecutive Patients.

Authors:  Guo-Chun Zha; Jun-Ying Sun; Kai-Jin Guo; Feng-Chao Zhao; Yong Pang; Xin Zheng
Journal:  J Arthroplasty       Date:  2016-02-09       Impact factor: 4.757

9.  Autogenous impaction grafting in total hip arthroplasty with developmental dysplasia of the hip.

Authors:  Huiwu Li; Liao Wang; Kerong Dai; Zhenan Zhu
Journal:  J Arthroplasty       Date:  2012-10-25       Impact factor: 4.757

10.  Long-term results of acetabular reconstruction using three bulk bone graft techniques in cemented total hip arthroplasty for developmental dysplasia.

Authors:  Kenichi Oe; Hirokazu Iida; Hiroshi Kawamura; Narumi Ueda; Tomohisa Nakamura; Naofumi Okamoto; Yusuke Ueda
Journal:  Int Orthop       Date:  2015-11-14       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.